Finnish health technology pioneer CurifyLabs, has acquired significant intellectual property (IP) from Mehta Heino Industries Oy, a Finnish 3D printing hardware development company. The acquisition marks a pivotal moment in CurifyLabs’ capability to offer unparalleled 3D printing solutions for producing personalized medicines in the pharma industry.
“The acquisition of Mehta Heino’s IP and other assets is a game-changer for us. Their innovative approach to 3D printing technology perfectly aligns with our vision enabling wider adoption of personalized treatments. This acquisition is not merely about growing our portfolio; it’s about leading the industry into a new era,” said Charlotta Topelius, Co-founder and CEO of CurifyLabs.
In addition to the IP acquisition, Petri Heino, CTO of Mehta Heino, has joined CurifyLabs as Lead Hardware Engineer. “CurifyLabs presents an extraordinary opportunity to push the boundaries of what is possible in 3D printing and advanced robotics in healthcare. Me and my Co-founder Santosh Mehta spent eight years developing our technology and we are thrilled to see our IP contribute to groundbreaking advancements for the benefit of vulnerable patient populations that need personalized treatments,” said Petri Heino.
CurifyLabs’ Pharma Kit solution, which combines innovative printable Pharma Inks with 3D printing technology and quality control, provides an automated solution for producing personalized medicine in hospitals and compounding pharmacies. The solution eliminates the manual process and makes compounding more accessible, cost-effective, safe, and scalable.
“For pharmacies, speed, seamless workflows, and regulatory compliance are essential. We enable this with our unique personalized medicine manufacturing solution. With Mehta Heino’s IP, we’re taking our commitment to effective solutions to the next level. Our combined expertise will result in more efficient manufacturing solutions, facilitating the wider adoption of personalized medicine and enhanced care for patients with individual needs,” said Niklas Sandler, Co-founder and CTO at CurifyLabs.
“We must pay special attention to pediatric populations where personalized medicines are crucial. The IP acquisition and adding Petri to our team enhance our ability to do just that,” said Charlotta Topelius.
